Literature DB >> 9024171

Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid.

J Y Chien1, R M Peter, C M Nolan, C Wartell, J T Slattery, S D Nelson, R L Carithers, K E Thummel.   

Abstract

OBJECTIVE: To determine in patients receiving isoniazid prophylaxis whether an increase in the CYP2E1 dependent formation clearance of acetaminophen (paracetamol) to N-acetyl-p-benzoquinone imine (NAPQI) occurs during a normal 24-hour isoniazid dose interval and whether the interaction is dependent on acetylation status.
METHODS: Acetaminophen elimination kinetics were determined on four different occasions. Ten subjects were assigned to receive acetaminophen either simultaneously with the 8 am dose of isoniazid or 12 hours after the isoniazid dose. One week later, on the last day of isoniazid therapy, subjects received acetaminophen at the alternate time of day. The control phase acetaminophen administrations were repeated 1 and 2 weeks later, following the initial randomization. Isoniazid acetylation (NAT2) genotype was determined by analysis of genomic DNA obtained from peripheral blood leukocytes.
RESULTS: The mean NAPQI formation clearance was inhibited 57% when acetaminophen and isoniazid were coadministered but was unchanged compared with time-matched control when acetaminophen was given 12 hours after the isoniazid dose. However, when data from subjects was segregated according to isoniazid (INH) acetylation phenotype, the mean ratio of NAPQI formation clearances (+INH/-INH) with 8 PM acetaminophen was significantly higher for fast acetylators compared with slow acetylators (1.36 versus 0.68; p = 0.006).
CONCLUSIONS: Fast metabolizers of isoniazid appeared to clear the inducer or inhibitor from the active site of CYP2E1 more rapidly, which resulted in an increased formation of NAPQI 12 hours after the isoniazid dose. In contrast, formation of NAPQI for slow isoniazid metabolizers remained inhibited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024171     DOI: 10.1016/S0009-9236(97)90179-X

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Effect of excipients on acetaminophen metabolism and its implications for prevention of liver injury.

Authors:  Michael Ganetsky; Mark Böhlke; Luis Pereira; David Williams; Barbara LeDuc; Shiva Guatam; Steven D Salhanick
Journal:  J Clin Pharmacol       Date:  2013-02-22       Impact factor: 3.126

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Felbamate in epilepsy therapy: evaluating the risks.

Authors:  J M Pellock
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

4.  PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Authors:  Ankit Balhara; Saranjit Singh
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

5.  Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation.

Authors:  Rick D Fannin; Mark Russo; Thomas M O'Connell; Kevin Gerrish; Jason H Winnike; Jeffrey Macdonald; Jack Newton; Shahid Malik; Stella O Sieber; Joel Parker; Ruchir Shah; Tong Zhou; Paul B Watkins; Richard S Paules
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 6.  Paracetamol: a focus for the general pediatrician.

Authors:  Pierluigi Marzuillo; Stefano Guarino; Egidio Barbi
Journal:  Eur J Pediatr       Date:  2013-12-28       Impact factor: 3.183

Review 7.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

Review 8.  Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?

Authors:  Sarbjeet S Kalsi; David M Wood; W Stephen Waring; Paul I Dargan
Journal:  Open Access Emerg Med       Date:  2011-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.